RxDoctor Payments DataLook up a doctor →

Dena Haddad, PA

Endocrinology, Diabetes & Metabolism · Scottsdale, AZNPI 1538870548

Payments from drug & device makers

$7,871in general payments, 2019–2025

Across 394 payments — averaging $19.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$2K
  • AbbVie$1K
  • UCB, Inc.$603
  • Lilly USA, LLC$471
  • Pfizer$409
  • AstraZeneca$402
  • plus $2K from 39 others

What the payments were for

  • Food & beverage$7,850100%
  • Education$210%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,871 in reported general payments places this provider in the 70th percentile of 148 endocrinology, diabetes & metabolism providers in Arizona.

See all endocrinology, diabetes & metabolism providers in Arizona

Medicare billing

Part B allowed, 2024
$13,891
Medicare patients
59
Services billed
382

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Enbrel SureclickEtanercept24$175,345
Hydroxychloroquine Sulfate105$6,369
MethotrexateMethotrexate Sodium134$3,824
Leflunomide45$3,391
Allopurinol36$1,445
Mycophenolate Mofetil20$1,339
Pilocarpine Hcl15$1,256
Colchicine13$975
Methylprednisolone69$660
Prednisone83$640
Sulfasalazine21$419
Tramadol Hcl33$380
Folic Acid19$164
Alendronate Sodium18$108

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Amneal Pharmaceuticals LLCMycophenolate Mofetil$39$1,33920 claims
Scilex Pharmaceuticals Inc.Colchicine$19$97513 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 148 endocrinology, diabetes & metabolism providers in Arizona.

Other endocrinology, diabetes & metabolism in Scottsdale

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →